InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.011 -0.304 (-96.51%)+
Announcement
Release
23 Jan 2026 5:41PM
Price at Release
$0.315
Full Release
download
Summary
Cynata Therapeutics Limited announced it has completed a $1.2 million At-The-Market raise utilizing its ATM Subscription Agreement with Acuity Capital by setting off 4.3 million shares previously issued under the ATM. The shares were set off at a discounted price, with the proceeds intended for working capital. Cynata is an Australian clinical-stage biotechnology firm focusing on stem cell therapeutics via its Cymerus™ platform, which addresses conventional MSC production limitations. The company is advancing its clinical trials for various indications, leveraging the benefits of its proprietary technology.
Key Points
  • Cynata Therapeutics Limited announced a $1.2m At-The-Market raise.
  • The company raised funds by setting off 4,300,000 shares issued to Acuity Capital.
  • Set-off shares had a deemed issue price of $0.28, which was an 11.1% discount.
  • Funds raised will be used for working capital.
  • Cynata specialises in cell therapeutics using its proprietary Cymerus™ platform.
  • Cymerus™ technology uses induced pluripotent stem cells for manufacturing MSCs.
  • Cynata is involved in multiple clinical trials for its product candidates.
  • Cynata's Cymerus™ technology has shown safety and efficacy in clinical trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.